{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:27Z","timestamp":1793410767860,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00228-026-04027-5","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T02:37:08Z","timestamp":1774665428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Physiologically based pharmacokinetic modeling for optimal dosage prediction of statins and warfarin in patients with liver cirrhosis"],"prefix":"10.1007","volume":"82","author":[{"given":"Naira","family":"Galal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha M","family":"El-Khodary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Hussien Ahmed","family":"Hussien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abdelkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"El-Khateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"4027_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP et al (2023) Global burden of liver disease: 2023 update. J Hepatol 79:516\u2013537. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017","journal-title":"J Hepatol"},{"key":"4027_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RNH Pugh","year":"1973","unstructured":"Pugh RNH, Murray-Lyon IM, Dawson JL et al (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646\u2013649. https:\/\/doi.org\/10.1002\/bjs.1800600817","journal-title":"Br J Surg"},{"key":"4027_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1389200043489054","volume":"5","author":"R Elbekai","year":"2004","unstructured":"Elbekai R, Korashy H, El-Kadi A (2004) The Effect of Liver Cirrhosis on the Regulation and Expression of Drug Metabolizing Enzymes. Curr Drug Metab 5:157\u2013167. https:\/\/doi.org\/10.2174\/1389200043489054","journal-title":"Curr Drug Metab"},{"key":"4027_CR4","unstructured":"Food and Drug Administration (2003) Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. https:\/\/www.fda.gov\/media\/71311\/download. Accessed 8 Jan 2026"},{"key":"4027_CR5","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/liv.15896","volume":"44","author":"K Gananandan","year":"2024","unstructured":"Gananandan K, Wiese S, M\u00f8ller S, Mookerjee RP (2024) Cardiac dysfunction in patients with cirrhosis and acute decompensation. Liver Int 44:1832\u20131841. https:\/\/doi.org\/10.1111\/liv.15896","journal-title":"Liver Int"},{"key":"4027_CR6","doi-asserted-by":"publisher","first-page":"G407","DOI":"10.1152\/ajpgi.00441.2016","volume":"312","author":"R Schierwagen","year":"2017","unstructured":"Schierwagen R, Uschner FE, Magdaleno F et al (2017) Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol 312:G407\u2013G412. https:\/\/doi.org\/10.1152\/ajpgi.00441.2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4027_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"4027_CR8","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL et al (2019) 2018 Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:e285\u2013350. https:\/\/doi.org\/10.1161\/CIR.0000000000000625","journal-title":"Circulation"},{"key":"4027_CR9","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jhep.2021.01.024","volume":"75","author":"P Caraceni","year":"2021","unstructured":"Caraceni P, Abraldes JG, Gin\u00e8s P et al (2021) The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 75:S118\u2013S134. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.024","journal-title":"J Hepatol"},{"key":"4027_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11938-022-00394-x","volume":"20","author":"C Moctezuma-Velazquez","year":"2022","unstructured":"Moctezuma-Velazquez C, Abraldes JG (2022) The Role of Statins in Cirrhosis. Curr Treat Options Gastroenterol 20:316\u2013335. https:\/\/doi.org\/10.1007\/s11938-022-00394-x","journal-title":"Curr Treat Options Gastroenterol"},{"key":"4027_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1124\/dmd.25.10.1191","volume":"25","author":"T Prueksaritanont","year":"1997","unstructured":"Prueksaritanont T, Gorham LM, Ma B et al (1997) In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191\u20131199. https:\/\/doi.org\/10.1124\/dmd.25.10.1191","journal-title":"Drug Metab Dispos"},{"key":"4027_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","volume":"42","author":"H Lennern\u00e4s","year":"2003","unstructured":"Lennern\u00e4s H (2003) Clinical Pharmacokinetics of Atorvastatin. Clin Pharmacokinet 42:1141\u20131160. https:\/\/doi.org\/10.2165\/00003088-200342130-00005","journal-title":"Clin Pharmacokinet"},{"key":"4027_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/S0090-9556(24)15086-6","volume":"28","author":"W Jacobsen","year":"2000","unstructured":"Jacobsen W, Kuhn B, Soldner A et al (2000) Lactonization Is the Critical First Step in the Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin. Drug Metab Dispos 28:1369\u20131378. https:\/\/doi.org\/10.1016\/S0090-9556(24)15086-6","journal-title":"Drug Metab Dispos"},{"key":"4027_CR14","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","volume":"130","author":"RH Ho","year":"2006","unstructured":"Ho RH, Tirona RG, Leake BF et al (2006) Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. Gastroenterology 130:1793\u20131806. https:\/\/doi.org\/10.1053\/j.gastro.2006.02.034","journal-title":"Gastroenterology"},{"key":"4027_CR15","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1124\/dmd.108.021410","volume":"36","author":"S Kitamura","year":"2008","unstructured":"Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin. Drug Metab Dispos 36:2014\u20132023. https:\/\/doi.org\/10.1124\/dmd.108.021410","journal-title":"Drug Metab Dispos"},{"key":"4027_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1124\/dmd.118.080523","volume":"46","author":"B Prasad","year":"2018","unstructured":"Prasad B, Bhatt DK, Johnson K et al (2018) Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. Drug Metab Dispos 46:943\u2013952. https:\/\/doi.org\/10.1124\/dmd.118.080523","journal-title":"Drug Metab Dispos"},{"key":"4027_CR17","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","volume":"18","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Achour B, Al-Majdoub ZM et al (2021) Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment. Mol Pharm 18:3563\u20133577. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00462","journal-title":"Mol Pharm"},{"key":"4027_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12876-021-01704-w","volume":"21","author":"S Sung","year":"2021","unstructured":"Sung S, Al-Karaghouli M, Kalainy S et al (2021) A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol 21:120. https:\/\/doi.org\/10.1186\/s12876-021-01704-w","journal-title":"BMC Gastroenterol"},{"key":"4027_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-002-0541-7","volume":"58","author":"SG Simonson","year":"2003","unstructured":"Simonson SG, Martin PD, Mitchell P et al (2003) Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 58:669\u2013675. https:\/\/doi.org\/10.1007\/s00228-002-0541-7","journal-title":"Eur J Clin Pharmacol"},{"key":"4027_CR20","unstructured":"(2019) Lipitor\u00ae [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020702s074lbl.pdf. Accessed 2 May 2025"},{"key":"4027_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1067\/mcp.2000.110216","volume":"68","author":"JJ Lilja","year":"2000","unstructured":"Lilja JJ, Kivist\u00f6 KT, Neuvonen PJ (2000) Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 68:384\u2013390. https:\/\/doi.org\/10.1067\/mcp.2000.110216","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2125.2004.02095.x","volume":"58","author":"JJ Lilja","year":"2004","unstructured":"Lilja JJ, Neuvonen M, Neuvonen PJ (2004) Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58:56\u201360. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02095.x","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0009-9236(98)90130-8","volume":"64","author":"JJ Lilja","year":"1998","unstructured":"Lilja JJ, Kivist\u00f6 KT, Neuvonen PJ (1998) Grapefruit juice\u2014simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477\u2013483. https:\/\/doi.org\/10.1016\/S0009-9236(98)90130-8","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1365-2125.2009.03385.x","volume":"67","author":"R Krishna","year":"2009","unstructured":"Krishna R, Garg A, Jin B et al (2009) Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 67:520\u2013526. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03385.x","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","volume":"94","author":"TA Jacobson","year":"2004","unstructured":"Jacobson TA (2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94:1140\u20131146. https:\/\/doi.org\/10.1016\/j.amjcard.2004.07.080","journal-title":"Am J Cardiol"},{"key":"4027_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1067\/mcp.2000.104609","volume":"67","author":"O MOUSA","year":"2000","unstructured":"MOUSA O, BRATER D, SUNDBLAD K, HALL S (2000) The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 67:267\u2013274. https:\/\/doi.org\/10.1067\/mcp.2000.104609","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0009-9236(98)90151-5","volume":"64","author":"T Kantola","year":"1998","unstructured":"Kantola T, Kivist\u00f6 KT, Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64:177\u2013182. https:\/\/doi.org\/10.1016\/S0009-9236(98)90151-5","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR28","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","volume":"25","author":"P Martin","year":"2003","unstructured":"Martin P (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553\u20132563. https:\/\/doi.org\/10.1016\/S0149-2918(03)80316-8","journal-title":"Clin Ther"},{"key":"4027_CR29","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL et al (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25:2822\u20132835. https:\/\/doi.org\/10.1016\/S0149-2918(03)80336-3","journal-title":"Clin Ther"},{"key":"4027_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bcp.12377","volume":"78","author":"T Prueksaritanont","year":"2014","unstructured":"Prueksaritanont T, Chu X, Evers R et al (2014) Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide clinical probe than rosuvastatin. Br J Clin Pharmacol 78:587\u2013598. https:\/\/doi.org\/10.1111\/bcp.12377","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","volume":"75","author":"D Schneck","year":"2004","unstructured":"Schneck D (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455\u2013463. https:\/\/doi.org\/10.1016\/j.clpt.2003.12.014","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0009-9236(02)17633-8","volume":"73","author":"K Cooper","year":"2003","unstructured":"Cooper K (2003) Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73:322\u2013329. https:\/\/doi.org\/10.1016\/S0009-9236(02)17633-8","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR33","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1177\/0091270011422815","volume":"52","author":"MK DeGorter","year":"2012","unstructured":"DeGorter MK, Urquhart BL, Gradhand U et al (2012) Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in Oatp1b2-\/\u2010 Mice and Intraindividual Variability in Human Subjects. J Clin Pharmacol 52:1689\u20131697. https:\/\/doi.org\/10.1177\/0091270011422815","journal-title":"J Clin Pharmacol"},{"key":"4027_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/cp.1999.v66.100453001","volume":"66","author":"J LILJA","year":"1999","unstructured":"LILJA J, KIVISTO K, NEUVONEN P (1999) Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 66:118\u2013127. https:\/\/doi.org\/10.1053\/cp.1999.v66.100453001","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1517\/13543784.2010.509342","volume":"19","author":"M Derks","year":"2010","unstructured":"Derks M, Abt M, Parr G et al (2010) No clinically relevant drug\u2013drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opin Investig Drugs 19:1135\u20131145. https:\/\/doi.org\/10.1517\/13543784.2010.509342","journal-title":"Expert Opin Investig Drugs"},{"key":"4027_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0009-9236(98)90023-6","volume":"64","author":"T Kantola","year":"1998","unstructured":"Kantola T, Kivist\u00f6 KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58\u201365. https:\/\/doi.org\/10.1016\/S0009-9236(98)90023-6","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","volume":"78","author":"J BACKMAN","year":"2005","unstructured":"BACKMAN J, LUURILA H, NEUVONEN M, NEUVONEN P (2005) Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78:154\u2013167. https:\/\/doi.org\/10.1016\/j.clpt.2005.04.007","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","volume":"81","author":"YY Lau","year":"2007","unstructured":"Lau YY, Huang Y, Frassetto L, Benet LZ (2007) Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers. Clin Pharmacol Ther 81:194\u2013204. https:\/\/doi.org\/10.1038\/sj.clpt.6100038","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00228-008-0534-2","volume":"64","author":"L Almeida","year":"2008","unstructured":"Almeida L, Falc\u00e3o A, Vaz-da-Silva M et al (2008) Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol 64:961\u2013966. https:\/\/doi.org\/10.1007\/s00228-008-0534-2","journal-title":"Eur J Clin Pharmacol"},{"key":"4027_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1365-2125.2012.04171.x","volume":"74","author":"R Krishna","year":"2012","unstructured":"Krishna R, Stypinski D, Ali M et al (2012) Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 74:116\u2013124. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04171.x","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR41","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1177\/009127009603601111","volume":"36","author":"S Liao","year":"1996","unstructured":"Liao S, Palmer M, Fowler C, Nayak RK (1996) Absence of an Effect of Levofloxacin on Warfarin Pharmacokinetics and Anticoagulation in Male Volunteers. J Clin Pharmacol 36:1072\u20131077. https:\/\/doi.org\/10.1177\/009127009603601111","journal-title":"J Clin Pharmacol"},{"key":"4027_CR42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1046\/j.1365-2125.2001.01358.x","volume":"51","author":"RA Yates","year":"2001","unstructured":"Yates RA, Wong J, Seiberling M et al (2001) The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 51:429\u2013435. https:\/\/doi.org\/10.1046\/j.1365-2125.2001.01358.x","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2125.2003.02051.x","volume":"57","author":"X Jiang","year":"2004","unstructured":"Jiang X, Williams KM, Liauw WS et al (2004) Effect of St John\u2019s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57:592\u2013599. https:\/\/doi.org\/10.1111\/j.1365-2125.2003.02051.x","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2125.2004.02160.x","volume":"58","author":"W Dieterle","year":"2004","unstructured":"Dieterle W, Corynen S, Mann J (2004) Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 58:433\u2013436. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02160.x","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR45","doi-asserted-by":"publisher","unstructured":"Paine M, Ngo, Brantley et al (2010) The warfarin\u2013cranberry juice interaction revisited: A systematic in vitro\u2013in vivo evaluation. J Exp Pharmacol 83. https:\/\/doi.org\/10.2147\/JEP.S11719","DOI":"10.2147\/JEP.S11719"},{"key":"4027_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0091270006294540","volume":"47","author":"H Oberwittler","year":"2007","unstructured":"Oberwittler H, Hirschfeld-Warneken A, Wesch R et al (2007) Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO\u2010Independent sGC Activator HMR1766. J Clin Pharmacol 47:70\u201377. https:\/\/doi.org\/10.1177\/0091270006294540","journal-title":"J Clin Pharmacol"},{"key":"4027_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1177\/0091270010370588","volume":"51","author":"LM Bavisotto","year":"2011","unstructured":"Bavisotto LM, Ellis DJ, Milner PG et al (2011) Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants. J Clin Pharmacol 51:561\u2013574. https:\/\/doi.org\/10.1177\/0091270010370588","journal-title":"J Clin Pharmacol"},{"key":"4027_CR48","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","volume":"24","author":"DJ Black","year":"1996","unstructured":"Black DJ, Kunze KL, Wienkers LC et al (1996) Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24:422\u2013428. https:\/\/doi.org\/10.1016\/S0090-9556(25)07369-6","journal-title":"Drug Metab Dispos"},{"key":"4027_CR49","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2125.2004.02323.x","volume":"59","author":"JJ Lilja","year":"2005","unstructured":"Lilja JJ, Backman JT, Neuvonen PJ (2005) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol 59:433\u2013439. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02323.x","journal-title":"Br J Clin Pharmacol"},{"key":"4027_CR50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/j.1538-7836.2011.04429.x","volume":"9","author":"A TRIPODI","year":"2011","unstructured":"TRIPODI A, ANSTEE QM, SOGAARD KK et al (2011) Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 9:1713\u20131723. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04429.x","journal-title":"J Thromb Haemost"},{"key":"4027_CR51","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1053\/j.gastro.2021.08.015","volume":"161","author":"RS O\u2019Shea","year":"2021","unstructured":"O\u2019Shea RS, Davitkov P, Ko CW et al (2021) AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology 161:1615\u20131627e1. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.015","journal-title":"Gastroenterology"},{"key":"4027_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000533161","volume":"31","author":"F Capinha","year":"2024","unstructured":"Capinha F, Noronha Ferreira C (2024) Management of Nonmalignant Portal Vein Thrombosis in Cirrhosis. GE Port J Gastroenterol 31:77\u201388. https:\/\/doi.org\/10.1159\/000533161","journal-title":"GE Port J Gastroenterol"},{"key":"4027_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41397-024-00329-y","volume":"24","author":"B Cross","year":"2024","unstructured":"Cross B, Turner RM, Zhang JE, Pirmohamed M (2024) Being precise with anticoagulation to reduce adverse drug reactions: are we there yet? Pharmacogenomics J 24:7. https:\/\/doi.org\/10.1038\/s41397-024-00329-y","journal-title":"Pharmacogenomics J"},{"key":"4027_CR54","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","volume":"71","author":"A Qamar","year":"2018","unstructured":"Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP (2018) Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol 71:2162\u20132175. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.023","journal-title":"J Am Coll Cardiol"},{"key":"4027_CR55","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/bjh.19734","volume":"205","author":"LN Roberts","year":"2024","unstructured":"Roberts LN, Thachil J (2024) Prevention and management of venous thrombosis in patients with cirrhosis. Br J Haematol 205:1717\u20131719. https:\/\/doi.org\/10.1111\/bjh.19734","journal-title":"Br J Haematol"},{"key":"4027_CR56","doi-asserted-by":"crossref","unstructured":"Portela CP, Gautier LA, Zermatten MG et al (2024) Direct oral anticoagulants in liver cirrhosis: rationale and current evidence. JHEP Rep 101116","DOI":"10.1016\/j.jhepr.2024.101116"},{"key":"4027_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/clpt.1980.137","volume":"28","author":"C Hignite","year":"1980","unstructured":"Hignite C, Uetrecht J, Tschanz C, Azarnoff D (1980) Kinetics of R and S warfarin enantiomers. Clin Pharmacol Ther 28:99\u2013105","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR58","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.1013","volume":"104","author":"M Shebley","year":"2018","unstructured":"Shebley M, Sandhu P, Emami Riedmaier A et al (2018) Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective. Clin Pharmacol Ther 104:88\u2013110. https:\/\/doi.org\/10.1002\/cpt.1013","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s13318-016-0353-2","volume":"42","author":"MF Rasool","year":"2017","unstructured":"Rasool MF, Khalil F, L\u00e4er S (2017) Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. Eur J Drug Metab Pharmacokinet 42:383\u2013396. https:\/\/doi.org\/10.1007\/s13318-016-0353-2","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4027_CR60","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/psp4.12901","volume":"12","author":"MK Ladumor","year":"2023","unstructured":"Ladumor MK, Storelli F, Liang X et al (2023) Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT Pharmacometrics Syst Pharmacol 12:261\u2013273. https:\/\/doi.org\/10.1002\/psp4.12901","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4027_CR61","doi-asserted-by":"publisher","first-page":"100362","DOI":"10.1016\/j.dmpk.2020.10.001","volume":"39","author":"Z Wang","year":"2021","unstructured":"Wang Z, Xiang X, Liu S et al (2021) A physiologically based pharmacokinetic\/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib. Drug Metab Pharmacokinet 39:100362. https:\/\/doi.org\/10.1016\/j.dmpk.2020.10.001","journal-title":"Drug Metab Pharmacokinet"},{"key":"4027_CR62","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/00498254.2023.2246153","volume":"53","author":"S Kollipara","year":"2023","unstructured":"Kollipara S, Ahmed T, Praveen S (2023) Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers. Xenobiotica 53:339\u2013356. https:\/\/doi.org\/10.1080\/00498254.2023.2246153","journal-title":"Xenobiotica"},{"key":"4027_CR63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.2125","volume":"110","author":"T Heimbach","year":"2021","unstructured":"Heimbach T, Chen Y, Chen J et al (2021) Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective. Clin Pharmacol Ther 110:297\u2013310. https:\/\/doi.org\/10.1002\/cpt.2125","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J et al (2009) Population-Based Mechanistic Prediction of Oral Drug Absorption. AAPS J 11:225\u2013237. https:\/\/doi.org\/10.1208\/s12248-009-9099-y","journal-title":"AAPS J"},{"key":"4027_CR65","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238\u20131257. https:\/\/doi.org\/10.1002\/jps.20502","journal-title":"J Pharm Sci"},{"key":"4027_CR66","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","volume":"24","author":"T Rodgers","year":"2007","unstructured":"Rodgers T, Rowland M (2007) Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes. Pharm Res 24:918\u2013933. https:\/\/doi.org\/10.1007\/s11095-006-9210-3","journal-title":"Pharm Res"},{"key":"4027_CR67","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1021\/jm300212s","volume":"55","author":"M Karlgren","year":"2012","unstructured":"Karlgren M, Vildhede A, Norinder U et al (2012) Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug\u2013Drug Interactions. J Med Chem 55:4740\u20134763. https:\/\/doi.org\/10.1021\/jm300212s","journal-title":"J Med Chem"},{"key":"4027_CR68","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0022-3565(25)24810-8","volume":"257","author":"DR Abernethy","year":"1991","unstructured":"Abernethy DR, Kaminsky LS, Dickinson TH (1991) Selective inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther 257:411\u2013415. https:\/\/doi.org\/10.1016\/S0022-3565(25)24810-8","journal-title":"J Pharmacol Exp Ther"},{"key":"4027_CR69","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpt1975184377","volume":"18","author":"GR Wilkinson","year":"1975","unstructured":"Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377\u2013390. https:\/\/doi.org\/10.1002\/cpt1975184377","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR70","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/aps.2012.103","volume":"33","author":"G Li","year":"2012","unstructured":"Li G, Wang K, Chen R et al (2012) Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol Sin 33:1359\u20131371. https:\/\/doi.org\/10.1038\/aps.2012.103","journal-title":"Acta Pharmacol Sin"},{"key":"4027_CR71","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-015-0253-7","volume":"54","author":"MF Rasool","year":"2015","unstructured":"Rasool MF, Khalil F, L\u00e4er S (2015) A Physiologically Based Pharmacokinetic Drug\u2013Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. Clin Pharmacokinet 54:943\u2013962. https:\/\/doi.org\/10.1007\/s40262-015-0253-7","journal-title":"Clin Pharmacokinet"},{"key":"4027_CR72","unstructured":"Crestor\u00ae. (2023) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021366s043s044lbl.pdf. Accessed 2 May 2025"},{"key":"4027_CR73","unstructured":"Coumadin\u00ae. (2011) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf. Accessed 2 May 2025"},{"key":"4027_CR74","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/j.dmd.2025.100056","volume":"53","author":"MA West","year":"2025","unstructured":"West MA, Lazzaro S, Morrow R et al (2025) Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions. Drug Metab Dispos 53:100056. https:\/\/doi.org\/10.1016\/j.dmd.2025.100056","journal-title":"Drug Metab Dispos"},{"key":"4027_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/phar.70007","volume":"45","author":"L Hooper","year":"2025","unstructured":"Hooper L, Liu S, Pai MP (2025) GLP-1RA\u2010induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy 45:211\u2013219. https:\/\/doi.org\/10.1002\/phar.70007","journal-title":"Pharmacotherapy"},{"key":"4027_CR76","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147\u20131161. https:\/\/doi.org\/10.1007\/s00228-008-0553-z","journal-title":"Eur J Clin Pharmacol"},{"key":"4027_CR77","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/cpt.1717","volume":"107","author":"M Drozdzik","year":"2020","unstructured":"Drozdzik M, Szelag-Pieniek S, Post M et al (2020) Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage. Clin Pharmacol Ther 107:1138\u20131148. https:\/\/doi.org\/10.1002\/cpt.1717","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR78","doi-asserted-by":"publisher","first-page":"122052","DOI":"10.1016\/j.talanta.2020.122052","volume":"225","author":"B Seyfinejad","year":"2021","unstructured":"Seyfinejad B, Ozkan SA, Jouyban A (2021) Recent advances in the determination of unbound concentration and plasma protein binding of drugs: Analytical methods. Talanta 225:122052. https:\/\/doi.org\/10.1016\/j.talanta.2020.122052","journal-title":"Talanta"},{"key":"4027_CR79","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","volume":"21","author":"M Tsutsuura","year":"2021","unstructured":"Tsutsuura M, Moriyama H, Kojima N et al (2021) The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis 21:153. https:\/\/doi.org\/10.1186\/s12879-021-05858-6","journal-title":"BMC Infect Dis"},{"key":"4027_CR80","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/cpt.3032","volume":"114","author":"BG Small","year":"2023","unstructured":"Small BG, Hatley O, Jamei M et al (2023) Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis. Clin Pharmacol Ther 114:1264\u20131273. https:\/\/doi.org\/10.1002\/cpt.3032","journal-title":"Clin Pharmacol Ther"},{"key":"4027_CR81","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1124\/dmd.123.001487","volume":"52","author":"AC Ozbey","year":"2024","unstructured":"Ozbey AC, Fowler S, Leys K et al (2024) Physiologically-Based Pharmacokinetic Modeling for Drugs Cleared by Non-Cytochrome P450 Enzymes: State-of-the-Art and Future Perspectives. Drug Metab Dispos 52:44\u201355. https:\/\/doi.org\/10.1124\/dmd.123.001487","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04027-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:37:42Z","timestamp":1776404262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04027-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4027"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04027-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eman El-Khateeb is an employee of Certara Predictive Technologies. The other authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}